This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université de Montréal directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid.
Neurobiology of disease · 2009
The transcription factors Nur77 and retinoid X receptors participate in amphetamine-induced locomotor activities.
Psychopharmacology · 2009
Nur77 and retinoid X receptors: crucial factors in dopamine-related neuroadaptation.
Trends in neurosciences · 2007 · senior author
Latest funding
- $497,170
The role of transcription factors Nur77 and retinoid X receptor (RXR) in the effect of antipsychotic drugs
CIHR · 2013 · Principal investigator
3 publications.
Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid.
Mahmoudi S, Samadi P, Gilbert F, Ouattara B, Morissette M, Grégoire L, Rouillard C, Di Paolo T, Lévesque D
The transcription factors Nur77 and retinoid X receptors participate in amphetamine-induced locomotor activities.
Bourhis E, Maheux J, Paquet B, Kagechika H, Shudo K, Rompré PP, Rouillard C, Lévesque D
Nur77 and retinoid X receptors: crucial factors in dopamine-related neuroadaptation.
Lévesque D, Rouillard C
The role of transcription factors Nur77 and retinoid X receptor (RXR) in the effect of antipsychotic drugs
Principal investigators: Levesque, Daniel; Rouillard, Claude
Keywords: Antipsychotic Drugs; Dopamine D2 Receptors; Drug-Induced Biomarker; Dyskinesia; Gene Expression; Neuropharmacology; Nuclear Receptors; Retinoids; Single Nucleotide Polymorphism; Transcription Factors
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.